Latest Articles
Henry Winkler explains why he finally sought therapy at 70 - Adelaide Now
Henry Winkler explains why he finally sought therapy at 70 Adelaide Now
Published: Sept. 10, 2026, 2:06 p.m.
New non-hormonal therapy for endometriosis wins MedChem Australia funding to fast-track drug discovery - Monash University
New non-hormonal therapy for endometriosis wins MedChem Australia funding to fast-track drug discovery Monash University
Published: Sept. 9, 2026, 11:29 a.m.
New non-hormonal therapy for endometriosis wins MedChem Australia funding to fast-track drug discovery - monash.edu
New non-hormonal therapy for endometriosis wins MedChem Australia funding to fast-track drug discovery monash.edu
Published: Sept. 9, 2026, 11:29 a.m.
The effect of intravenous remdesivir on endometrial receptivity in female mice.
Pregnant women with coronavirus disease 2019 (COVID-19) are more likely than nonpregnant women to require admission to an intensive care unit, and many may require antiviral therapy. Remdesivir, an antiviral …
Published: Sept. 9, 2026, midnight
Research Progress of Histone Deacetylase and Its Inhibitors in Endometriosis.
Endometriosis is a complex chronic inflammatory disease with an unclear etiology and limited treatment options, severely affecting the reproductive health and quality of life of many women. Histone deacetylases (HDACs), …
Published: Sept. 9, 2026, midnight
Endometriosis Menstrual Pain Dropped to Minimal or No Pain After a Median of 8 Weeks With Relugolix Therapy - Gilmore Health
Endometriosis Menstrual Pain Dropped to Minimal or No Pain After a Median of 8 Weeks With Relugolix Therapy Gilmore Health
Published: Sept. 5, 2026, 10:35 a.m.
Endometriosis Menstrual Pain Dropped to Minimal or No Pain After a Median of 8 Weeks With Relugolix Therapy - gilmorehealth.com
Endometriosis Menstrual Pain Dropped to Minimal or No Pain After a Median of 8 Weeks With Relugolix Therapy gilmorehealth.com
Published: Sept. 5, 2026, 10:35 a.m.
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Published: Sept. 5, 2026, midnight
FocalTherics' Ryan Rhodes: Focal One HIFU Is Building a Prostate Therapy Category, Not Just a Device - finance.biggo.com
FocalTherics' Ryan Rhodes: Focal One HIFU Is Building a Prostate Therapy Category, Not Just a Device finance.biggo.com
Published: Sept. 3, 2026, 1:08 p.m.
Monitoring Safety and Symptom Relief During Endometriosis Therapy - Contemporary OB/GYN
Monitoring Safety and Symptom Relief During Endometriosis Therapy Contemporary OB/GYN
Published: Sept. 2, 2026, 1:07 p.m.
Link copied to clipboard!